The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation

被引:15
作者
López-Pérez, R
García-Sanz, R
González, D
Balanzategui, A
Chillón, MC
Alaejos, I
Mateos, MV
Caballero, MD
Mateo, G
Nieto, MJ
González, M
San Miguel, JF
机构
[1] Univ Hosp Salamanca, Dept Hematol, Serv Hematol, Salamanca 37007, Spain
[2] Univ Salamanca, Ctr Invest Canc, E-37008 Salamanca, Spain
关键词
myeloma; IgH gene; rearrangement; apheresis; transplantation;
D O I
10.1038/sj.leu.2401862
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the present paper, we report on the use of the heteroduplex PCR technique to detect the presence of clonally rearranged VDJ segments of the heavy chain immunoglobulin gene (VDJH) in the apheresis products of patients with multiple myeloma (MM) undergoing autologous peripheral blood stem cell (APBSC) transplantation. Twenty-three out of 31 MM patients undergoing APBSC transplantation with VDJH segments clonally rearranged detected at diagnosis were included in the study. Samples of the apheresis products were PCR amplified using J(H) and V-H (FRIII and FRII) consensus primers and subsequently analyzed with the heteroduplex technique, and compared with those obtained at diagnosis. 52% of cases yielded positive results (presence of clonally rearranged VDJH segments in at least one apheresis), The presence of positive results in the apheresis products was not related to any pretransplant characteristics with the exception of response status at transplant. Thus, while no one patient with positive apheresis products was in complete remission (CR), negative immunofixation, before the transplant, five cases (46%) with negative apheresis were already in CR at transplant (P = 0.01). The remaining six cases with heteroduplex PCR negative apheresis were in partial remission before transplant. Patients with clonally free products were more likely to obtain CR following transplant (64% vs 17%, P = 0.02) and a longer progression-free survival, (40 months in patients transplanted with polyclonal products vs 20 with monoclonal ones, P = 0.03). These results were consistent when the overall survival was considered, since it was better in those patients with negative apheresis than it was in those with positive (83% vs 36% at 5 years from diagnosis, P = 0.01), These findings indicate that the presence of clonality rearranged VDJH segments is related to the response and outcome in MM transplanted patients.
引用
收藏
页码:1493 / 1499
页数:7
相关论文
共 36 条
  • [1] Autologous peripheral blood stem cell transplantation for multiple myeloma:: a report of 259 cases from the Spanish registry
    Alegre, A
    Díaz-Mediavilla, J
    San-Miguel, J
    Martínez, R
    Laraña, JG
    Sureda, A
    Lahuerta, JJ
    Morales, D
    Bladé, J
    Caballero, D
    De la Rubia, J
    Escudero, A
    Díez-Martín, JL
    Hernández-Navarro, F
    Rifón, J
    Odriozola, J
    Brunet, S
    De la Serna, J
    Besalduch, J
    Vidal, MJ
    Solano, C
    Leon, A
    Sánchez, JJ
    Martínez-Chamorro, C
    Fernández-Rañada, JM
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (02) : 133 - 140
  • [2] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    Attal, M
    Harousseau, JL
    Stoppa, AM
    Sotto, JJ
    Fuzibet, JG
    Rossi, JF
    Casassus, P
    Maisonneuve, H
    Facon, T
    Ifrah, N
    Payen, C
    Bataille, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) : 91 - 97
  • [3] BIRD JM, 1993, BONE MARROW TRANSPL, V12, P651
  • [4] Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
  • [5] Diagnosis, prognosis, and standard treatment of multiple myeloma
    Boccadoro, M
    Pileri, A
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (01) : 111 - &
  • [6] GENE MARKING TO DETERMINE WHETHER AUTOLOGOUS MARROW INFUSION RESTORES LONG-TERM HEMATOPOIESIS IN CANCER-PATIENTS
    BRENNER, MK
    RILL, DR
    HOLLADAY, MS
    HESLOP, HE
    MOEN, RC
    BUSCHLE, M
    KRANCE, RA
    SANTANA, VM
    ANDERSON, WF
    IHLE, JN
    [J]. LANCET, 1993, 342 (8880) : 1134 - 1137
  • [7] *CHRON LEUK MYEL T, 1973, CANC CHEMOTHER REP, V4, P141
  • [8] Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
    Corradini, P
    Voena, C
    Tarella, C
    Astolfi, M
    Ladetto, M
    Palumbo, A
    Van Lint, MT
    Bacigalupo, A
    Santoro, A
    Musso, M
    Majolino, I
    Boccadoro, M
    Pileri, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 208 - 215
  • [9] HIGH-DOSE SEQUENTIAL CHEMORADIOTHERAPY IN MULTIPLE-MYELOMA - RESIDUAL TUMOR-CELLS ARE DETECTABLE IN BONE-MARROW AND PERIPHERAL-BLOOD CELL HARVESTS AND AFTER AUTOGRAFTING
    CORRADINI, P
    VOENA, C
    ASTOLFI, M
    LADETTO, M
    TARELLA, C
    BOCCADORO, M
    PILERI, A
    [J]. BLOOD, 1995, 85 (06) : 1596 - 1602
  • [10] Cremer FW, 1998, EXP HEMATOL, V26, P969